dc.contributor.author |
Siddik-Sayyid S.M. |
dc.contributor.author |
Yazbeck-Karam V.G. |
dc.contributor.author |
Zahreddine B.W. |
dc.contributor.author |
Adham A.M.B.F. |
dc.contributor.author |
Dagher C.M. |
dc.contributor.author |
Saasouh W.A. |
dc.contributor.author |
Aouad M.T. |
dc.contributor.editor |
|
dc.date |
Jul-2010 |
dc.date.accessioned |
2017-10-05T15:29:08Z |
dc.date.available |
2017-10-05T15:29:08Z |
dc.date.issued |
2010 |
dc.identifier |
10.1111/j.1399-6576.2010.02231.x |
dc.identifier.isbn |
|
dc.identifier.issn |
00015172 |
dc.identifier.uri |
http://hdl.handle.net/10938/15106 |
dc.description.abstract |
Background: Subarachnoid (SA) morphine, highly effective for the management of pain after a cesarean delivery, is associated with a significant incidence of pruritus in up to 80percent of patients. No previous study has compared the effectiveness of ondansetron (5-HT3 antagonist) vs. diphenhydramine (H1 receptor blocker) for the treatment of this side effect. Methods: In this randomized, double-blind study, 113 patients with a pruritus score 3 or 4 (1=absent; 2=mild, no treatment required; 3=moderate pruritus, treatment required; and 4=severe pruritus) after SA morphine 0.2 mg were assigned to group ondansetron, which received 4 mg intravenously (i.v.) ondansetron, and group diphenhydramine, which received 25 mg i.v. diphenhydramine. Patients who continued to have pruritus ≥3 30 min after the study drug were considered treatment failures and were treated with naloxone 0.04 mg i.v. repeatedly, as well as patients who relapsed. Pain scores, nausea, vomiting, and sedation were determined before and 30 min after the study drugs were administered. Patients were followed up for 24 h. Results: The success rate was comparable between the two groups [40-57 (70percent) and 38-56 (70percent), P=0.79, in group ondansetron and group diphenhydramine, respectively]. Among the successfully treated patients, the recurrence rates of moderate to severe pruritus were 11-40 (28percent) in group ondansetron and 13-38 (35percent) in group diphenhydramine, P=0.52. The side effect profile was similar between the two groups. Conclusion: Ondansetron is as effective as diphenhydramine in relieving pruritus caused by SA morphine in patients undergoing a cesarean delivery. However, up to 50percent of patients required naloxone either for primary failure or for recurrence. © 2010 The Authors. |
dc.format.extent |
|
dc.format.extent |
Pages: (764-769) |
dc.language |
English |
dc.publisher |
MALDEN |
dc.relation.ispartof |
Publication Name: Acta Anaesthesiologica Scandinavica; Publication Year: 2010; Volume: 54; no. 6; Pages: (764-769); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Ondansetron is as effective as diphenhydramine for treatment of morphine-induced pruritus after cesarean delivery |
dc.type |
Article |
dc.contributor.affiliation |
Siddik-Sayyid, S.M., Department of Anesthesiology, American University of Beirut, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Yazbeck-Karam, V.G., Department of Anesthesiology, Rizk Hospital, Beirut, Lebanon |
dc.contributor.affiliation |
Zahreddine, B.W., Department of Anesthesiology, American University of Beirut, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Adham, A.M.B.F., Department of Anesthesiology, American University of Beirut, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Dagher, C.M., Department of Anesthesiology, American University of Beirut, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Saasouh, W.A., Department of Anesthesiology, American University of Beirut, Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Aouad, M.T., Department of Anesthesiology, American University of Beirut, Medical Center, Beirut, Lebanon |
dc.contributor.authorAddress |
Aouad, M. T.; Department of Anesthesiology, American University of Beirut, PO Box 11-0236, Beirut, Lebanon; email: mm01@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Anesthesiology; |
dc.contributor.authorDepartment |
Anesthesiology |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
mm01@aub.edu.lb |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Siddik-Sayyid, SM |
dc.contributor.authorInitials |
Yazbeck-Karam, VG |
dc.contributor.authorInitials |
Zahreddine, BW |
dc.contributor.authorInitials |
Adham, AMBF |
dc.contributor.authorInitials |
Dagher, CM |
dc.contributor.authorInitials |
Saasouh, WA |
dc.contributor.authorInitials |
Aouad, MT |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Aouad, MT (reprint author), Amer Univ Beirut, Dept Anesthesiol, Med Ctr, POB 11-0236, Beirut, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Alhashemi JA, 1997, CAN J ANAESTH, V44, P1060; Beilin Y, 1998, ANESTH ANALG, V86, P310, DOI 10.1097-00000539-199802000-00018; Bergland A, 2008, ACTA ANAESTH SCAND, V52, P1394, DOI 10.1111-j.1399-6576.2008.01782.x; Borgeat A, 1999, ANESTHESIOLOGY, V90, P432, DOI 10.1097-00000542-199902000-00017; CHADWICK HS, 1988, ANESTHESIOLOGY, V68, P925, DOI 10.1097-00000542-198806000-00015; Charuluxananan S, 2003, ANESTH ANALG, V96, P1789, DOI 10.1213-01.ANE.0000066015.21364.7D; Charuluxananan S, 2000, REGION ANESTH PAIN M, V25, P535, DOI 10.1053-rapm.2000.7809; COHEN SE, 1992, ANESTH ANALG, V75, P747; George RB, 2009, ANESTH ANALG, V109, P174, DOI 10.1213-ane.0b013e3181a45a6b; Jensen K, 2007, ACTA ANAESTH SCAND, V51, P464, DOI 10.1111-j.1399-6576.2006.01251.x; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046-j.0265-0215.2000.00826.x; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165-00003495-200059020-00005; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097-00000542-199902000-00018; RAWAL N, 1986, ANESTHESIOLOGY, V64, P194, DOI 10.1097-00000542-198602000-00011; ROILA F, 1995, CLIN PHARMACOKINET, V29, P95, DOI 10.2165-00003088-199529020-00004; SAIAH M, 1994, ANESTH ANALG, V78, P1110; Sarvela PJ, 2006, ACTA ANAESTH SCAND, V50, P239, DOI 10.1111-j.1399-6576.2006.00934.x; Siddik-Sayyid SM, 2007, ANESTH ANALG, V104, P421, DOI 10.1213-01.ane.0000253668.10453.de; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016-S0952-8180(03)00501-9; Tu RH, 2006, GASTROINTEST ENDOSC, V63, P87, DOI 10.1016-j.gie.2005.08.015; Yang T, 1999, CAN J ANAESTH, V46, P856; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097-00000539-200007000-00032 |
dc.description.citedCount |
4 |
dc.description.citedTotWOSCount |
4 |
dc.description.citedWOSCount |
4 |
dc.format.extentCount |
6 |
dc.identifier.articleNo |
|
dc.identifier.coden |
AANEA |
dc.identifier.pubmedID |
20236094 |
dc.identifier.scopusID |
77953159985 |
dc.identifier.url |
|
dc.publisher.address |
COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Acta Anaesthesiol. Scand. |
dc.relation.ispartOfIssue |
6 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Acta Anaesthesiologica Scandinavica |
dc.relation.ispartofPubTitleAbbr |
Acta Anaesthesiol. Scand. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
54 |
dc.source.ID |
WOS:000278292400015 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
diphenhydramine, 147-24-0, 58-73-1 |
dc.subject.otherChemCAS |
morphine, 52-26-6, 57-27-2 |
dc.subject.otherChemCAS |
naloxone, 357-08-4, 465-65-6 |
dc.subject.otherChemCAS |
ondansetron, 103639-04-9, 116002-70-1, 99614-01-4 |
dc.subject.otherChemCAS |
Diphenhydramine, 58-73-1 |
dc.subject.otherChemCAS |
Histamine H1 Antagonists |
dc.subject.otherChemCAS |
Morphine, 57-27-2 |
dc.subject.otherChemCAS |
Naloxone, 465-65-6 |
dc.subject.otherChemCAS |
Narcotic Antagonists |
dc.subject.otherChemCAS |
Narcotics |
dc.subject.otherChemCAS |
Ondansetron, 99614-02-5 |
dc.subject.otherChemCAS |
Serotonin Antagonists |
dc.subject.otherIndex |
diphenhydramine |
dc.subject.otherIndex |
morphine |
dc.subject.otherIndex |
naloxone |
dc.subject.otherIndex |
ondansetron |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
cesarean section |
dc.subject.otherIndex |
clinical trial |
dc.subject.otherIndex |
controlled clinical trial |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
double blind procedure |
dc.subject.otherIndex |
drug efficacy |
dc.subject.otherIndex |
drug safety |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
follow up |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
nausea and vomiting |
dc.subject.otherIndex |
pain assessment |
dc.subject.otherIndex |
patient satisfaction |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
pruritus |
dc.subject.otherIndex |
randomized controlled trial |
dc.subject.otherIndex |
recurrence risk |
dc.subject.otherIndex |
sedation |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Cesarean Section |
dc.subject.otherIndex |
Diphenhydramine |
dc.subject.otherIndex |
Double-Blind Method |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Histamine H1 Antagonists |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Morphine |
dc.subject.otherIndex |
Naloxone |
dc.subject.otherIndex |
Narcotic Antagonists |
dc.subject.otherIndex |
Narcotics |
dc.subject.otherIndex |
Ondansetron |
dc.subject.otherIndex |
Pain, Postoperative |
dc.subject.otherIndex |
Patient Satisfaction |
dc.subject.otherIndex |
Postoperative Nausea and Vomiting |
dc.subject.otherIndex |
Pregnancy |
dc.subject.otherIndex |
Pruritus |
dc.subject.otherIndex |
Recurrence |
dc.subject.otherIndex |
Serotonin Antagonists |
dc.subject.otherIndex |
Severity of Illness Index |
dc.subject.otherKeywordPlus |
OPIOID-INDUCED PRURITUS |
dc.subject.otherKeywordPlus |
INTRATHECAL MORPHINE |
dc.subject.otherKeywordPlus |
EPIDURAL-MORPHINE |
dc.subject.otherKeywordPlus |
POSTCESAREAN ANALGESIA |
dc.subject.otherKeywordPlus |
PREVENTION |
dc.subject.otherKeywordPlus |
NALOXONE |
dc.subject.otherKeywordPlus |
SECTION |
dc.subject.otherKeywordPlus |
NALBUPHINE |
dc.subject.otherKeywordPlus |
PROPOFOL |
dc.subject.otherKeywordPlus |
NAUSEA |
dc.subject.otherWOS |
Anesthesiology |